search
Back to results

Study of XL999 in Patients With Non-small Cell Lung Cancer

Primary Purpose

Non-small Cell Lung Cancer

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
XL999
Sponsored by
Symphony Evolution, Inc.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-small Cell Lung Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Males and females with histologically confirmed NSCLC Prior treatment with a platinum- or taxane containing regimen Stage IIIB with malignant effusion, stage IV or recurrent NSCLC that is not amenable to curative therapy (either surgery or radiation therapy) Measurable disease according to Response Criteria for Solid Tumors (RECIST) ECOG performance status of 0 or 1 Life expectancy ≥3 months Adequate organ and marrow function No other malignancies within 5 years Signed informed consent Exclusion Criteria: Radiation to ≥25% of bone marrow within 30 days of XL999 treatment Use of any systemic anticancer therapy within 30 days of XL999 treatment More than 2 prior systemic cytotoxic chemotherapy regimens More than 1 prior agent targeted against VEGF or EGFR (eg, bevacizumab, erlotinib, or gefitinib) Subject has not recovered to ≤ grade 1 or to within 10% of baseline from adverse events due to other medications administered >30 days before study enrollment Uncontrolled and/or intercurrent illness History of or known brain metastases, current spinal cord compression, or carcinomatous meningitis Pregnant or breastfeeding females Known HIV

Sites / Locations

  • Hematology/Oncology Associates of the Treasure Coast
  • Joliet Oncology-Hematology Associates, Ltd.
  • Hematology-Oncology Associates of Rockland
  • Center for Oncology Research and Treatment, PA

Outcomes

Primary Outcome Measures

Response rate
Safety and tolerability

Secondary Outcome Measures

Progression-free survival
Duration of response
Overall survival
Pharmacokinetic (PK) and Pharmacodynamic (PD) parameters

Full Information

First Posted
January 12, 2006
Last Updated
February 18, 2010
Sponsor
Symphony Evolution, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00277329
Brief Title
Study of XL999 in Patients With Non-small Cell Lung Cancer
Official Title
A Phase 2 Study of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
February 2010
Overall Recruitment Status
Terminated
Why Stopped
Study was terminated due to cardiac toxicities in the subejcts
Study Start Date
December 2005 (undefined)
Primary Completion Date
August 2007 (Actual)
Study Completion Date
July 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Symphony Evolution, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with non-small cell lung cancer (NSCLC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-small Cell Lung Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
9 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
XL999
Intervention Description
• The Study Treatment Period, in which subjects received a once-weekly, 4-hour intravenous (IV) infusion of XL999 at 2.4 mg/kg as outpatients for 8 weeks. Treatment was to be stopped at the occurrence of disease progression or unacceptable toxicity.
Primary Outcome Measure Information:
Title
Response rate
Time Frame
Inclusion until disease progression
Title
Safety and tolerability
Time Frame
Inclusion until 30 dyas post last treatment
Secondary Outcome Measure Information:
Title
Progression-free survival
Time Frame
Inclusion until disease progression
Title
Duration of response
Time Frame
Inclusion until disease progression
Title
Overall survival
Time Frame
Inclusion until 180-Day Follow-up post last treatment or death
Title
Pharmacokinetic (PK) and Pharmacodynamic (PD) parameters
Time Frame
Various time points during the 8-week Study Treatment Period in the second stage of the study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males and females with histologically confirmed NSCLC Prior treatment with a platinum- or taxane containing regimen Stage IIIB with malignant effusion, stage IV or recurrent NSCLC that is not amenable to curative therapy (either surgery or radiation therapy) Measurable disease according to Response Criteria for Solid Tumors (RECIST) ECOG performance status of 0 or 1 Life expectancy ≥3 months Adequate organ and marrow function No other malignancies within 5 years Signed informed consent Exclusion Criteria: Radiation to ≥25% of bone marrow within 30 days of XL999 treatment Use of any systemic anticancer therapy within 30 days of XL999 treatment More than 2 prior systemic cytotoxic chemotherapy regimens More than 1 prior agent targeted against VEGF or EGFR (eg, bevacizumab, erlotinib, or gefitinib) Subject has not recovered to ≤ grade 1 or to within 10% of baseline from adverse events due to other medications administered >30 days before study enrollment Uncontrolled and/or intercurrent illness History of or known brain metastases, current spinal cord compression, or carcinomatous meningitis Pregnant or breastfeeding females Known HIV
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paul Woodard, MD
Organizational Affiliation
Exelixis
Official's Role
Study Director
Facility Information:
Facility Name
Hematology/Oncology Associates of the Treasure Coast
City
Port St. Lucie
State/Province
Florida
ZIP/Postal Code
34952
Country
United States
Facility Name
Joliet Oncology-Hematology Associates, Ltd.
City
Joliet
State/Province
Illinois
ZIP/Postal Code
60435
Country
United States
Facility Name
Hematology-Oncology Associates of Rockland
City
Nyack
State/Province
New York
ZIP/Postal Code
10960
Country
United States
Facility Name
Center for Oncology Research and Treatment, PA
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Study of XL999 in Patients With Non-small Cell Lung Cancer

We'll reach out to this number within 24 hrs